Protocol of REACH-01: a single-arm, open label, prospective study of HAIC sequential TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma
Key Technology Research and Development Program of Shandong
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article
Protocol of REACH-01: a single-arm, open label, prospective study of HAIC sequential TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma
Tingguo Zhang, Kangshuai Li, Zongli Zhang, Yunfei Xu et al.
Citations
1 citations
Journal
Frontiers in Pharmacology
Topics
Cholangiocarcinoma and Gallbladder Cancer Studies
Field-Weighted Citation Impact (FWCI)
0.57
article
Protocol of REACH-01: a single-arm, open label, prospective study of HAIC sequential TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma
Tingguo Zhang, Kangshuai Li, Zongli Zhang, Yunfei Xu, Yi Liu
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Frontiers in PharmacologyVol. 15
Institutions
Qilu Hospital of Shandong University (CN)
Funders
BeiGene, Key Technology Research and Development Program of Shandong